BioCrossroads

BioCrossroads, established in 2002, is an Indiana-based organization dedicated to advancing the state's life sciences industry. It facilitates growth by fostering collaborations among corporate, academic, and philanthropic partners, investing in promising early-stage startups, and supporting enterprise development. Additionally, BioCrossroads educates through conferences, reports, and market development knowledge, aiming to improve global patient health and boost Indiana's economic growth.

Nora Doherty

EVP Strategy, Managing Director Seed Fund

Vince Wong JD

CEO and President

David Johnson

President and CEO

24 past transactions

Gate Neurosciences

Venture Round in 2022
Gate Neurosciences is a healthcare company based in Carmel, Indiana, specializing in the development of innovative neuronal therapeutics aimed at treating central nervous system disorders, including psychiatric and neurologic diseases. Founded in 2018, the company focuses on next-generation targeted therapies that utilize precision medicine to create breakthrough drugs. Its therapeutic approach enhances neuroplasticity, strengthens neuronal connections, and rebalances signaling within the brain, thereby restoring healthy brain function and addressing the underlying pathophysiology of various conditions. By prioritizing the creation of safe, potent, and rapid-acting treatments, Gate Neurosciences aims to provide effective solutions for both patients and healthcare providers dealing with central nervous system disorders.

Lumavate

Venture Round in 2022
Lumavate operates a cloud-based software platform that enables manufacturers to enhance customer experiences for their products via mobile engagement. The company facilitates this by transforming product labels into interactive channels, providing users with relevant information such as repair guides and authentic part sourcing. Lumavate serves diverse industries including infrastructure, outdoor, and industrial sectors. Founded in 2015 and based in Carmel, Indiana, the company specializes in building progressive web apps (PWAs) at scale to deliver personalized mobile experiences throughout the customer journey.

Kovina Therapeutics

Seed Round in 2021
Kovina Therapeutics is a preclinical biotechnology company focused on developing non-surgical, medical treatments for Human Papillomavirus (HPV) infections and associated cancers. The company's approach involves creating antiviral therapeutics that target and inactivate a specific HPV protein consistently expressed in early-stage infections and cancers. This targeted strategy aims to enable medical practitioners to treat patients infected with HPV and HPV-related cancers without the need for surgery.

Novosteo

Series A in 2021
Novosteo Inc. is a biotechnology company based in West Lafayette, Indiana, founded in 2017. The firm specializes in developing and manufacturing innovative drugs aimed at healing bone fractures and addressing related conditions that significantly impact patients' morbidity, mortality, and quality of life. With scientific guidance from co-founders Stewart Low and Philip Low of Purdue University, Novosteo utilizes a proprietary chemistry approach to bone targeting, which allows for the delivery of anabolic agents directly to fracture surfaces. This unique method focuses on accelerating bone regeneration and improving healing outcomes, thereby mitigating the debilitating effects associated with bone injuries and enhancing patient mobility and productivity.

Sabanto

Convertible Note in 2020
Sabanto is a company that offers a Farming-as-a-Service solution aimed at enhancing autonomy in agricultural machinery. It specializes in low-cost retrofitting of existing agricultural equipment, irrespective of brand or model, and develops software that supports the functionality of autonomous technology. This approach not only improves the utility of farming equipment but also aims to increase the return on investment for producers. Sabanto's technology facilitates comprehensive agricultural services through a supervised autonomous equipment platform, allowing farmers to monitor and operate their operations efficiently from a centralized location. By focusing on simple and cost-effective innovations, Sabanto is dedicated to advancing the future of agriculture.

MBX Biosciences

Series A in 2020
MBX Biosciences, Inc. is a biotechnology company founded in 2018 and based in Carmel, Indiana. The company specializes in developing therapeutics for rare endocrine disorders, focusing on conditions that currently lack effective treatments. MBX Biosciences aims to discover, develop, and commercialize first-in-class therapies, particularly peptides designed to address endocrine genetic diseases that affect glandular hormone production and the body’s chemical messaging systems.

Sexton Biotechnologies

Venture Round in 2019
Sexton Biotechnologies is a biotechnology company founded in 2019 and based in Indianapolis, Indiana. It specializes in developing and selling bioproduction tools specifically designed for cell and gene therapy. The company focuses on creating tools and media that facilitate flexible automation and scaling in cell manufacturing processes, ultimately aiming to enhance clinical outcomes. Sexton Biotechnologies is recognized for its innovative container closure and media supplementation solutions, which are essential for the bioproduction of cell and gene therapies. Through ongoing research and product development, the company seeks to expand its market presence and commercialize its offerings effectively.

Sabanto

Seed Round in 2019
Sabanto is a company that offers a Farming-as-a-Service solution aimed at enhancing autonomy in agricultural machinery. It specializes in low-cost retrofitting of existing agricultural equipment, irrespective of brand or model, and develops software that supports the functionality of autonomous technology. This approach not only improves the utility of farming equipment but also aims to increase the return on investment for producers. Sabanto's technology facilitates comprehensive agricultural services through a supervised autonomous equipment platform, allowing farmers to monitor and operate their operations efficiently from a centralized location. By focusing on simple and cost-effective innovations, Sabanto is dedicated to advancing the future of agriculture.

Lumavate

Venture Round in 2019
Lumavate operates a cloud-based software platform that enables manufacturers to enhance customer experiences for their products via mobile engagement. The company facilitates this by transforming product labels into interactive channels, providing users with relevant information such as repair guides and authentic part sourcing. Lumavate serves diverse industries including infrastructure, outdoor, and industrial sectors. Founded in 2015 and based in Carmel, Indiana, the company specializes in building progressive web apps (PWAs) at scale to deliver personalized mobile experiences throughout the customer journey.

OmniVis

Grant in 2018
OmniVis is a biotechnology company that has developed a portable pathogen detection platform aimed at improving the speed, accuracy, and affordability of pathogen testing. Its ultrasensitive handheld device provides a cost-effective alternative to traditional laboratory testing by delivering accurate results in under 30 minutes directly at the source. The platform is designed to analyze swabs or liquid samples, enabling health organizations to detect various pathogens efficiently. By utilizing single-use disposable test kits in conjunction with its handheld hardware, OmniVis allows for rapid and reliable pathogen measurement, significantly reducing the time to detection while remaining user-friendly and accessible.

Scioto Biosciences

Series A in 2018
Scioto Biosciences, founded in 2017 and headquartered in Indianapolis, Indiana, specializes in the development of an Activated Bacterial Therapeutics (ABT) platform. This platform enables the delivery of live, active therapeutic bacteria to the gut, allowing them to persist and adhere to intestinal mucosa. The company's focus is on advancing microbiome therapeutics for various diseases associated with the central nervous system and gastrointestinal tract, aiming to enhance healing through its synbiotic-activated formulation.

Allinaire Therapeutics

Seed Round in 2018
Allinaire Therapeutics, LLC is a biotechnology company based in Cleveland, Ohio, established in 2015. The company focuses on developing innovative therapeutics for chronic obstructive pulmonary disease (COPD) and other pulmonary diseases, including pulmonary arterial hypertension (PAH). Allinaire's research is grounded in the discovery of a novel therapeutic target identified by its scientific founders, Irina Petrache, MD, and Matthias Clauss, Ph.D., which plays a critical role in the development and progression of lung disease. By targeting this mechanism, Allinaire Therapeutics aims to create treatment options that could significantly enhance clinical outcomes for patients suffering from various cardiopulmonary conditions.

SonarMed

Series C in 2017
SonarMed, Inc. is a medical device company based in Carmel, Indiana, founded in 2005 to enhance the placement and monitoring of endotracheal tubes for patients unable to breathe independently. The company's flagship product, SonarMed AirWave, employs acoustic reflectometry technology to provide real-time, precise monitoring of endotracheal tube position and function. This non-invasive device aids healthcare providers in detecting potentially hazardous conditions related to breathing tubes, thereby improving patient safety and care quality. By offering a comprehensive approach to the management of endotracheal tubes, SonarMed aims to reduce the risks associated with their use and enhance the overall efficacy of respiratory interventions in clinical settings.

Scioto Biosciences

Grant in 2016
Scioto Biosciences, founded in 2017 and headquartered in Indianapolis, Indiana, specializes in the development of an Activated Bacterial Therapeutics (ABT) platform. This platform enables the delivery of live, active therapeutic bacteria to the gut, allowing them to persist and adhere to intestinal mucosa. The company's focus is on advancing microbiome therapeutics for various diseases associated with the central nervous system and gastrointestinal tract, aiming to enhance healing through its synbiotic-activated formulation.

SpeechVive

Seed Round in 2016
SpeechVive Inc. is a medical technology company based in Lafayette, Indiana, that focuses on developing innovative communication solutions for individuals with Parkinson's disease. Founded in 2011, the company specializes in the design and manufacture of a wearable speech device aimed at enhancing the speech capabilities of patients. This device effectively reduces background noise, thereby improving the user's ability to hear and facilitating increased speech volume and clarity. By addressing the communication challenges faced by those with Parkinson's disease, SpeechVive aims to help patients lead more normal and fulfilling lives.

Calibrium

Convertible Note in 2015
Calibrium is a privately-held biopharmaceutical company dedicated to the development of innovative drug candidates aimed at treating diabetes and related metabolic diseases. Co-founded by Fritz French, who serves as Chief Executive Officer, and Richard DiMarchi, PhD, the company's Chief Scientific Officer, Calibrium is focused on advancing its portfolio to address pressing health challenges associated with metabolic disorders.

Assembly Pharma

Venture Round in 2014
Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV). CpAMs can alter the activities of the HBV core protein, a unique viral protein with no human analogue that is involved in multiple stages of the HBV life cycle. In contrast to current therapies that only suppress HBV, Assembly Pharmaceutical’s CpAMs may have curative potential by eliminating the viral reservoir in infected individuals. Hepatitis B infection has a worldwide prevalence of over 350 million and more than 600,000 people die every year from complications associated with chronic HBV. Assembly has operations in Indiana and San Francisco.

Apexian Pharmaceuticals

Venture Round in 2013
Apexian Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, that specializes in developing innovative compounds for cancer treatment. Founded in 2007, the company is focused on its lead drug candidate, APX3330, which is an oral anticancer agent targeting the APE1/Ref-1 redox protein, a molecule associated with various cancers, including those of the colon, lung, breast, and pancreas. Apexian's research is grounded in the scientific discoveries of Dr. Mark R. Kelley, whose work on APE1/Ref-1 has illuminated this biological target's potential. In addition to its primary focus on cancer, the company is also involved in developing therapies for other diseases, including age-related macular degeneration and inflammatory bowel disease, aiming to provide safe and effective treatment options for patients.

Diagnotes

Series A in 2013
Diagnotes, Inc. is a digital healthcare company based in Indianapolis, Indiana, that specializes in enhancing communication and collaboration within the healthcare industry. Founded in 2010, Diagnotes offers a clinical communication platform designed for secure messaging, provider scheduling, patient data management, and documentation of discussions. The platform is tailored to the natural communication habits of healthcare professionals and their patients, facilitating seamless interactions among patients, physicians, care teams, hospitals, and other healthcare entities. Diagnotes serves a diverse clientele, including large health systems, community hospitals, long-term care facilities, and behavioral health organizations. Its applications are versatile, enabling uses from simple secure messaging to telehealth consultations, particularly beneficial for connecting specialists with patients in rural areas through live video. The platform's user-friendly design promotes quick implementation and adoption, making it an integral tool for managing patient-related communications effectively.

SonarMed

Series A in 2010
SonarMed, Inc. is a medical device company based in Carmel, Indiana, founded in 2005 to enhance the placement and monitoring of endotracheal tubes for patients unable to breathe independently. The company's flagship product, SonarMed AirWave, employs acoustic reflectometry technology to provide real-time, precise monitoring of endotracheal tube position and function. This non-invasive device aids healthcare providers in detecting potentially hazardous conditions related to breathing tubes, thereby improving patient safety and care quality. By offering a comprehensive approach to the management of endotracheal tubes, SonarMed aims to reduce the risks associated with their use and enhance the overall efficacy of respiratory interventions in clinical settings.

Bioscience Vaccines

Seed Round in 2010
Bioscience Vaccines, Inc. is a life sciences company based in West Lafayette, Indiana, specializing in the development of a proprietary vaccine adjuvant technology known as the Matrix Immune Modulator. This innovative technology, which originated in the laboratory of Dr. Mark Suckow at the University of Notre Dame and was further developed at Purdue University, enables the formulation of companion products that enhance existing vaccines approved by the FDA for preventing various infectious diseases in humans and animals. In addition to its focus on vaccine adjuvants, Bioscience Vaccines is also engaged in research aimed at exploring immunotherapeutic treatments for cancer through tissue vaccines, demonstrating its commitment to advancing medical solutions in both infectious diseases and oncology.

ImmuneWorks

Seed Round in 2007
ImmuneWorks, Inc. is a biotechnology company based in Indianapolis, Indiana, focused on developing innovative immune tolerance therapies for the treatment of idiopathic pulmonary fibrosis and other fibrotic lung diseases. Founded in 2006, ImmuneWorks aims to provide safe and effective treatments for patients suffering from serious autoimmune diseases affecting the lungs. The company is built upon a significant scientific discovery that identifies antigen-specific autoimmunity as a contributing factor in over half of idiopathic pulmonary fibrosis cases. Through its research and development efforts, ImmuneWorks seeks to transform the lives of patients by addressing the underlying causes of these debilitating conditions.

FlowCo

Seed Round in 2007
FlowCo is a medical device company developing products to improve the flow of blood through the vascular system.

CS-Keys

Seed Round in 2006
CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.